Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.
about
Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosisAntifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosisRecommendations for the Treatment of Invasive Fungal Infections in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-1)Clinical Translation of Nanomedicine.Severe hepatic injury associated with lipid formulations of amphotericin B.Lipid-based amphotericin B for the treatment of fungal infections.Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion.Administration of liposomal agents and blood clearance capacity of the mononuclear phagocyte system.Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits.Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinicSafety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.Review of comparative studies between conventional and liposomal amphotericin B (Ambisome) in neutropenic patients with fever of unknown origin and patients with systemic mycosis.It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drugEradication of severe neonatal systemic candidiasis with amphotericin B lipid complex.The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug.Liposomal amphotericin B therapy of murine histoplasmosis.Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patientsClinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacyAdverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis.Amphotericin B.Effects of the aggregation state of amphotericin B on its toxicity to mice.Optimizing efficacy of amphotericin B through nanomodification.Outcomes associated with conventional versus lipid-based formulations of amphotericin B in propensity-matched groupsSafety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.Nanoparticle systems as tools to improve drug delivery and therapeutic efficacy.Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony-stimulating factor, and surgery: report of five cases.Comparison of the effects of liposomal amphotericin B and conventional amphotericin B on propafenone metabolism and hepatic cytochrome P-450 in ratsPharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studiesStrategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patientsInvasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery--case report and review of the literature.Liposomes in the treatment of infections.Amphotericin B and its delivery by liposomal and lipid formulations.Liposomes as carriers of antimicrobial agents or immunomodulatory agents in the treatment of infections.Fungal endocarditis--a report on seven cases and a brief review.Infections in neutropenic patients. II: Management.Diversity of lipid-based polyene formulations and their behavior in biological systems.Modulation of amphotericin B activity by association with mannose ester.Ionic Driven Embedment of Hyaluronic Acid Coated Liposomes in Polyelectrolyte Multilayer Films for Local Therapeutic Delivery.
P2860
Q24187765-0A7A865B-C4AE-49F0-A7E8-28AEBF992327Q24202783-BE30D711-F302-413C-93B2-3C5CB66E79B7Q26824260-9390C8B6-BB23-4C30-A0C8-B1B2194356CFQ30355939-D8EA1B18-308B-455E-9F8D-4BAC1A6FCF86Q32068660-FD7B8A8C-C974-4840-9545-4FA0059BD2DDQ33604227-83B92EDD-0EEF-4D12-81D9-8B650EC72E50Q33691165-6BDB092E-6346-4242-B82E-458DF92E7838Q33694095-69D219CA-A03C-4277-9A43-3D42E90DEA97Q33697079-B0CFFE40-2D06-47E8-A21D-C33DEF27A5D8Q33752450-698DDAE6-78EF-40F6-A6C3-08B7B5212D1FQ33911056-BBF7EC5B-8BFC-42D1-8961-A8EA66F3867EQ33983629-17224C8A-55DE-40AA-B239-C7236998BA92Q34062371-06558C1A-8320-4E6C-A197-48FA9A6D4AA2Q34098069-369FB978-5A23-4BCE-A872-90228432AF82Q34302880-0148A793-255A-4742-8049-85D4217A9C03Q34382518-B9CF54AC-C8F3-4643-82E7-80D31B583871Q34596780-D55E46CB-FADC-4F4B-94E5-30683D64A8D6Q35117788-8D38EBAA-B106-451A-976F-D5814580133AQ35136556-918CA879-6CBA-48C4-B68B-47BE6D7A6F72Q35679856-4548FD88-68E2-401E-8FD8-9ABE26740AADQ36042366-04D11A02-9720-4A02-8E84-7E403D43B4C5Q36094404-8000FC96-9BB5-4738-91B7-102047B794C5Q36757947-D3205651-3E66-4D05-8285-B30CFAC2FE13Q36920328-B0ECF36E-5917-4758-8CB2-341D2331B663Q37260918-70F7F2B1-A334-450C-BB56-109DB51A3CC2Q37613070-C1FC0141-24D9-49E3-BB0F-89E1ED423824Q38123458-BD40A523-F701-4D9F-B955-9F2F4D99B383Q39419588-CE35001D-B5A9-4528-99DB-0AF5F439EC88Q39472605-F89DE590-EF37-4D49-9676-568F0D9167A5Q39785066-893F10D3-CC04-4971-92EF-45C37C30EF2EQ39866778-2DB59B0A-106C-4DE8-A6DF-25D0A5AFAEA5Q40435312-7B716968-B993-4070-AF09-02B5867A9F8FQ40499095-374653F8-D6E0-47BE-8D20-10A077F41C95Q40831603-4F8F2C61-F278-4811-9742-DEA54205A6CDQ40899101-6E00A037-B3A8-458A-9C74-5C59144A4A67Q41148087-6E2770CA-0BBD-40D9-A207-EB57E333FBD7Q41164565-8DB01208-3227-4AC2-B9ED-07C9893A8CC8Q41378026-35165F19-8EC5-4A5A-857E-42C146AEDC81Q41452863-72DF2244-AE3B-4F64-A0C7-353C469B9FFCQ41543808-6C5E7CFA-3DD5-4280-B682-F6FCA990BF38
P2860
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.
description
1991 nî lūn-bûn
@nan
1991 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.
@ast
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.
@en
type
label
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.
@ast
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.
@en
prefLabel
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.
@ast
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.
@en
P2093
P356
P1476
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.
@en
P2093
P356
10.1093/JAC/28.SUPPL_B.83
P407
P478
28 Suppl B
P577
1991-10-01T00:00:00Z